Two things are well established about buprenorphine withdrawal. It is real, because chronic use produces physical dependence of the opioid type [1]. And it is described on the medicine’s own label as moderate, appearing after abrupt discontinuation or a rapid reduction [1].
One thing is not established, and most pages on this subject gloss over it. No federal or World Health Organization source publishes a day-by-day withdrawal timeline for buprenorphine. We looked, and the section below says exactly where we looked.
This page covers the symptoms, the precipitated kind of withdrawal that is specific to this medicine, what supervision adds, and what the months afterwards look like. Our overview of buprenorphine in treatment covers the medicine itself.
Usually not in itself. The danger sits on either side of it.
The WHO’s guidance on withdrawal management is direct about the experience. Opioid withdrawal can be very uncomfortable and difficult, and it can feel like a very bad flu. It is not usually life-threatening [3]. The label matches that, describing the withdrawal that follows abrupt discontinuation or a rapid reduction as moderate [1].
There are exceptions the same guidance names. Pregnant women who are opioid dependent are advised not to undergo opioid withdrawal at all, because it can cause miscarriage or premature delivery, and methadone maintenance is the recommended approach instead [3]. That is a rule about who should not go through this, not a detail.
The real hazard arrives afterwards. Withdrawal reduces a person’s tolerance, so someone who has just come through it can overdose on a much smaller amount than they used to take [5]. That is why coming off anything without a plan for what follows is the riskiest version of stopping.
If someone is having a seizure, is unresponsive or has trouble breathing, call 911. For a mental-health crisis call or text 988.
Three clusters, and people usually notice them in this order.
The autonomic group comes first and is the most visible. MedlinePlus lists hot or cold flushes, sweating, chills, teary eyes and a runny nose among the symptoms of stopping buprenorphine or buprenorphine and naloxone too quickly [2]. The WHO’s opioid withdrawal list adds perspiration and a watery discharge from the eyes and nose [3].
The gut group is the one that sends people to a clinic. MedlinePlus names vomiting and diarrhea [2]. The WHO adds nausea and stomach cramps [3]. Fluid loss is the practical risk here, particularly in someone already unwell.
The muscular and nervous group is the one that lasts. MedlinePlus names restlessness and muscle pain [2]; the WHO names muscle cramps, anxiety and insomnia [3]. Sleep tends to be the last thing to settle.
None of that is a diagnosis of anything. Our page on withdrawal symptoms sets out how these compare across drug classes, and our section on prescription drug addiction covers the wider picture.
Because no source we can cite publishes one, and inventing it would be worse than admitting it.
Here is where we checked. SAMHSA’s TIP 45 Chapter 4 gives onset and duration per drug, and its worked examples are heroin and methadone [4]. It discusses buprenorphine at length, but as a medicine used to manage withdrawal, not as a substance with a withdrawal course of its own [4]. The WHO guidance splits opioid withdrawal into short-acting and long-acting categories, naming heroin and methadone as the examples [3]. Buprenorphine gets no category.
The page’s own primary source does say two things about the shape of it, and they belong here. The label’s Dependence section states that chronic administration produces physical dependence of the opioid type, characterized by moderate withdrawal signs and symptoms upon abrupt discontinuation or rapid taper, and that the withdrawal syndrome is typically milder than seen with full agonists and may be delayed in onset [1]. Milder and later is not a timeline, but it is the expectation to carry: someone who stops and feels fine for a day or two, and then does not, is seeing what the label describes.
We will not borrow the methadone figures. That is a deliberate rule here: a per-drug figure applied to a different drug is simply wrong, and the people most likely to be frightened by a timeline are the ones it does not fit.
What can be said is why the shape differs from heroin. Buprenorphine is long-acting. Taken under the tongue or against the cheek, it has a mean elimination half-life ranging from 24 to 42 hours [1]. Naloxone, the second component, clears much faster, with a mean elimination half-life of 2 to 12 hours [1]. A medicine that leaves slowly does not produce the same sharp curve a short-acting opioid does.
Supervised withdrawal and what follows it, in central Florida
The Recovery Village Umatilla is in Umatilla, Florida, and its own page publishes medical detox, inpatient treatment for substance use, inpatient rehab for mental health, partial hospitalization programming, outpatient programming and aftercare planning. We run four campuses in Florida, so ask admissions which one is nearest you and which of them runs the level of care your assessment recommends.
See treatment options in Florida Verify your insurance
The Recovery Village Umatilla is part of our family of treatment centers. See the Recovery Village Umatilla campus.
This is the part that belongs on a Suboxone page and almost nowhere else.
Buprenorphine binds very tightly to the mu-opioid receptor. TIP 45 explains that it has great affinity for that receptor despite being only a partial agonist, and can displace other opioids such as heroin [4]. Displacing them is the problem. TIP 45 says this feature gives buprenorphine the ability to precipitate opioid withdrawal in patients who have recently used heroin [4].
The label says the same thing in its own words. Because of buprenorphine’s partial agonist properties, the medicine may precipitate opioid withdrawal signs and symptoms if it is given before the effects of the other opioid have subsided [1].
So withdrawal here can be brought on by taking the medicine, not by stopping it. That reverses what most people assume, and it explains why starting treatment is timed rather than immediate.
Two details matter. People dependent on methadone or other long-acting opioids may be more susceptible to precipitated and prolonged withdrawal when treatment begins [1]. And naloxone, the second ingredient, is a potent antagonist that produces withdrawal signs in people physically dependent on full opioid agonists when it is injected [1]. That is why misusing the film by injection or through the nose can bring on withdrawal rather than a high [1].
Four things, and only one of them is willpower-adjacent.
The liver comes first. The label reports higher plasma levels and longer half-lives for both buprenorphine and naloxone in people with moderate or severe liver impairment, with the larger effect on naloxone [1]. In mild impairment, and in people with hepatitis C showing no sign of impairment, it reports no clinically significant change [1].
Other medicines come second. Drugs that inhibit the CYP3A4 enzyme raise buprenorphine levels; inducers lower them, and a falling level can itself bring on a withdrawal syndrome in someone whose body has adapted [1].
Other substances come third. Where alcohol or sedatives are also involved, the opioid withdrawal may not be the one that needs the most attention.
Fourth is how the stopping happened. The label ties the moderate withdrawal picture specifically to abrupt discontinuation or a rapid reduction [1], and MedlinePlus says stopping too quickly can cause symptoms [2]. A plan made with the prescriber who wrote the prescription is the difference.
Measurement, medication for symptoms, and somebody to change the plan.
The WHO guidance describes monitoring patients regularly for symptoms and complications, and using a short opioid withdrawal scale to track severity and choose the response [3]. Scoring beats guessing, and it means a problem is noticed before the person in it has to argue for help.
Symptomatic treatment is the second part, aimed at the things withdrawal actually does: nausea, cramps, anxiety and sleeplessness [3]. For moderate to severe opioid withdrawal, the same guidance describes managing it with opioid medication under review rather than leaving someone to endure it [3].
The third part is the one an article cannot supply. If the plan is not holding, the setting changes. Our explainer on medical detox covers what that involves, and our page on how long rehab takes covers the stage after it.
The acute phase is not the whole story, and people are rarely warned about this.
The WHO guidance states that acute opioid withdrawal is followed by a protracted withdrawal phase lasting up to six months, characterized by a general feeling of reduced well-being and strong cravings for opioids [3]. That figure is the WHO’s statement about opioid withdrawal generally rather than about buprenorphine specifically, and this page does not pretend otherwise.
What it means practically is that the difficult part is not over when the symptoms stop. Low mood, poor sleep and cravings can persist long after anyone would still call it withdrawal. Someone who expected to feel normal by a given week, and does not, is at their most vulnerable precisely because they think something has gone wrong.
Combine that with the tolerance point above and you have the case for aftercare in one sentence [5]. Our overview of medication assisted treatment covers the option of staying on medication, which remains a legitimate outcome rather than a failure.
Withdrawal management is the beginning of treatment, not a substitute for it.
The Recovery Village Umatilla publishes six levels of care on its own page: medical detox, inpatient treatment for substance use, inpatient rehab for mental health, partial hospitalization programming, outpatient programming and aftercare planning [6]. Where mental health is part of the picture, having inpatient mental health care on the same campus matters, because a transfer between providers is where plans usually break.
Which level fits is decided at assessment, with the full history in front of a clinician. Our levels of care explainer describes what separates them, and inpatient rehab and outpatient care cover the two ends. Our page on how admission works sets out the order of events, and our guide to whether insurance covers rehab explains what a benefits check produces.
No federal or WHO source publishes a day-by-day timeline for buprenorphine, so this page states none. What is known is that buprenorphine is long-acting, with a mean elimination half-life of 24 to 42 hours taken under the tongue or against the cheek, and that the label describes the withdrawal syndrome as typically milder than seen with full agonists and says it may be delayed in onset. The WHO does say that acute opioid withdrawal is followed by a protracted phase lasting up to six months, with reduced well-being and strong cravings.
That is not a decision to make alone. MedlinePlus is explicit that you should not stop taking buprenorphine, or buprenorphine and naloxone, without talking to your doctor, and that stopping too quickly can cause withdrawal symptoms. The safety issue is what comes after: withdrawal lowers tolerance, so a return to opioid use can cause an overdose at a much smaller amount than before. If someone is having a seizure, is unresponsive or has trouble breathing, call 911. For a mental health crisis, call or text 988.
We cannot answer that with a number, because no source we cite gives a buprenorphine-specific course. The label describes the withdrawal after abrupt discontinuation or a rapid reduction as moderate. A supervised setting scores symptoms as they happen with a short opioid withdrawal scale rather than predicting them from a calendar, which is more useful than any day count.
Yes, and the approach is decided clinically. The WHO guidance describes symptomatic treatment for nausea, cramps, anxiety and sleeplessness, and describes managing moderate to severe opioid withdrawal with opioid medication under daily review. Staying on buprenorphine is also a legitimate outcome rather than a failure. No amounts appear on this page by design.
Often, though the answer belongs to your policy rather than to an article. Marketplace plans have to cover substance use disorder services as an essential health benefit, and plans cannot apply annual or lifetime dollar limits to them. What your own plan pays for a given level of care, and what it wants authorized first, is a question for the plan or for an admissions team running a benefits check – ask for one on the first call rather than the last. Our guide to whether insurance covers rehab explains what that check does and does not settle.
This page is for general information and is not medical advice. Only a licensed clinician who knows your history can tell you what is right for you. If you or someone you know is in immediate danger, call 911. For free, confidential support 24/7, call or text 988.
Get cost-effective, quality addiction care that truly works.
Start Your Recovery